noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)
ImmuCell Corporation

Corporate Presentation (Investor Relations April 2026 Final)
Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5

Healthcare

Pappas Capital LLC

02/29/2016 | Press release | Archived content

Thrasos Announces Promising Results for Phase 2 THR-184 Dose Rang...

News | 02. 29. 2016

Thrasos Therapeutics

MONTREAL Canada & Boston MA, February 29, 2016 - Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today announced it has successfully completed its Phase 2, first-in-patients, dose ranging, clinical study of THR-184 for the prevention of acute kidney injury (AKI) in at risk patients undergoing cardiac surgery (NCT01830920). In the study, there was a reduction in the incidence of AKI in patients treated with the highest dose and THR-184 was safe and well tolerated. The effect was observed across different definitions of AKI and was most prominent in patients with underlying chronic kidney disease (CKD), which is an important risk factor for AKI.

Pappas Capital LLC published this content on February 29, 2016, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format